Export
export
Export
PDF
Excel (XLSX)
Word (DOCX)
You can select particular sections to be included in the output file.
Select all
Select classic EML layout
Indication
ICD-11
ATC codes
List type
Formulations
Therapeutic alternatives
Footnote
INN
Medicine type
Antibiotic groups
Sex
Age
Age restriction
Weight restriction
Patent information
Expert Committee decision justification
Cancel
Download
Model List of Essential Medicines
clear
Found 16 recommendations for 16 medicines and 0 therapeutic equivalents
Removed medicines and rejected applications are not shown.
Show them
.
6.4.4. Antihepatitis medicines
Daclatasvir
General information
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
Indications
Chronic hepatitis C
Daclatasvir + sofosbuvir
General information
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 60 mg + 400 mg
Indications
Chronic hepatitis C
Dasabuvir
General information
Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 250 mg tablet
Indications
Chronic hepatitis C
Entecavir
General information
Section
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 0.05 mg per mL
Oral > Solid: 0.5 mg; 1 mg
Indications
Chronic hepatitis B
Glecaprevir + pibrentasvir
General information
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
Indications
Chronic hepatitis C
Ledipasvir + sofosbuvir
General information
Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 90 mg + 400 mg tablet
Indications
Chronic hepatitis C
Ombitasvir + paritaprevir + ritonavir
General information
Section
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
Indications
Chronic hepatitis C
Pegylated interferon alfa (2a)
General information
Section
Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
Indications
Chronic hepatitis C
Pegylated interferon alfa (2b)
General information
Section
Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
Indications
Chronic hepatitis C
Ribavirin
General information
Section
Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg
Indications
Chronic hepatitis C
Sofosbuvir
General information
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 400 mg; 200 mg
Indications
Chronic hepatitis C
Sofosbuvir + velpatasvir
General information
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet
Indications
Chronic hepatitis C
Tenofovir disoproxil fumarate
General information
Section
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
Indications
Chronic hepatitis B